Comparison of Insulin Glargine Versus NPH Insulin in People with Type 2 Diabetes Mellitus Under Outpatient-Clinic Conditions for 18 Months Using a Basal-Bolus Regimen with a Rapid-Acting Insulin Analogue as Mealtime Insulin

 

 Buy Article Permissions and Reprints

Abstract

Aims: To assess the effects of a structured in-patient diabetes training programme in people with Type 2 diabetes mellitus on a basal-bolus regimen using insulin glargine or NPH insulin and rapid-acting insulin analogues with respect to glycaemic control, weight development and incidence of hypoglycaemia in an outpatient-clinic setting.

Patients and Methods: This was a prospective, non-randomized, single centre, comparative observational study including 119 subjects. Pre-study treatment was a basal-bolus regimen with NPH insulin and a rapid-acting insulin analogue. Subjects either continued with NPH insulin (n=56) or were switched over to insulin glargine (n=63) at the discretion of the investigator (aiming at equal numbers in each group). Patients then attended routine out-patient follow up visits for 18 months.

Results: HbA1c in the insulin glargine group improved statistically significant by -0.49%; [95%CI, -0.26, -0.71; p<0.001; HbA1c at endpoint 6.95±0.71%], whereas in the NPH group the reduction by -0.12% [95%CI, -0.31, 0.06; p=0.189; HbA1c at endpoint 7.22±0.74%] was statistically not significant. After 18 months of treatment the difference between treatment groups was 0.37% (p<0.015). Mean weight gain was significantly higher in the NPH group than in the glargine group (2.1 vs. 0.25 kg; p=0.025). A lower risk of hypoglycaemia in the glargine group (0.50 vs. 0.71 episodes/patient/month) did not reach statistical significance (p=0.081).

Conclusions: Following a structured in-patient diabetes training programme glycaemic control in people with Type 2 diabetes mellitus on a basal-bolus regimen improved significantly only with insulin glargine suggesting that training alone may not be sufficient to further improve metabolic control in relatively well controlled patients on NPH insulin. Therefore, in addition to a structured training programme also the insulin regimen should be optimized, e.g. by introduction of an insulin analogue.

References

• 1 Cavan D, Cradock S. Structured education programmes and type 2 diabetes.  Diabet Med. 2004;  21 ((Suppl 1)) 10-12
  PubMedGoogle Scholar
• 2 Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S. et al . Functional and molecular defects of pancreatic islets in human type 2 diabetes.  Diabetes. 2005;  54 727-735
  CrossrefPubMedGoogle Scholar
• 3 Garg SK. New insulin analogues.  Diabetes Technol Ther. 2005;  7 813-817
  CrossrefPubMedGoogle Scholar
• 4 Hirsch IB. Insulin analogues.  N Engl J Med. 2005;  352 174-183
  CrossrefPubMedGoogle Scholar
• 5 Karl DM. The use of bolus insulin and advancing insulin therapy in type 2 diabetes.  Curr Diab Rep. 2004;  4 352-357
  CrossrefPubMedGoogle Scholar
• 6 LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities.  Am J Med. 2002;  113 ((Suppl 6A)) 3S-11S
  CrossrefPubMedGoogle Scholar
• 7 Lindstrom T, Hedman CA, Arnqvist HJ. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.  Diabetes Care. 2002;  25 1049-1054
  CrossrefPubMedGoogle Scholar
• 8 Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities.  Diabetes Metab. 2006;  32 7-13
  CrossrefPubMedGoogle Scholar
• 9 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c.  Diabetes Care. 2003;  26 881-885
  CrossrefPubMedGoogle Scholar
• 10 Rosenstock J, Daily G, Massi-Benedetti M, Fritsche A, Lin Z, Salzmann A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.  Diabetes Care. 2005;  28 950-955
  CrossrefPubMedGoogle Scholar
• 11 Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.  Diabetologia. 2005;  48 1988-1995
  CrossrefPubMedGoogle Scholar
• 12 Stumvoll M, Goldstein BJ, Haeften TW van. Type 2 diabetes: principles of pathogenesis and therapy.  Lancet. 2005;  365 1333-1346
  CrossrefPubMedGoogle Scholar
• 13 Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.  JAMA. 1999;  281 2005-2012
  CrossrefPubMedGoogle Scholar
• 14 Yki-Yarvinnen H. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.  Eur J Clin Invest. 2004;  34 410-416
  CrossrefPubMedGoogle Scholar

Correspondence

T. Siegmund

Teaching Hospital Munich-Bogenhausen

Department for Endocrinology

Diabetes and Vascular Medicine

Englschalkinger Street 77

81925 Munich

Germany

Phone: +49/89/9270 21 11

Fax: +49/89/9270 21 16

Email: thorsten_siegmund@gmx.de